|
humans |
1077 |
|
female |
862 |
|
male |
811 |
|
adult |
762 |
|
middle aged |
611 |
|
aged |
580 |
|
animals |
565 |
|
hong kong |
535 |
|
medical sciences |
487 |
|
chinese |
462 |
|
adolescent |
461 |
|
risk factors |
362 |
|
mice |
338 |
|
china |
336 |
|
aged, 80 and over |
327 |
|
child |
321 |
|
covid-19 |
311 |
|
hong kong - epidemiology |
311 |
|
time factors |
311 |
|
treatment outcome |
306 |
|
prognosis |
294 |
|
prevalence |
290 |
|
apoptosis |
287 |
|
epidemiology |
276 |
|
quality of life |
260 |
|
immunohistochemistry |
251 |
|
retrospective studies |
248 |
|
molecular sequence data |
242 |
|
reverse transcriptase polymerase chain reaction |
242 |
|
prospective studies |
236 |
|
base sequence |
234 |
|
cell line |
229 |
|
rats |
227 |
|
incidence |
226 |
|
cells, cultured |
225 |
|
follow-up studies |
225 |
|
child, preschool |
222 |
|
cohort studies |
222 |
|
cell line, tumor |
217 |
|
cancer |
209 |
|
young adult |
209 |
|
pregnancy |
208 |
|
mutation |
206 |
|
sensitivity and specificity |
202 |
|
age factors |
198 |
|
nasopharyngeal carcinoma |
197 |
|
infant |
192 |
|
case-control studies |
191 |
|
asian continental ancestry group |
188 |
|
gene expression |
188 |
|
genotype |
188 |
|
children |
187 |
|
hepatocellular carcinoma |
186 |
|
human |
186 |
|
blotting, western |
182 |
|
amino acid sequence |
180 |
|
depression |
180 |
|
inflammation |
180 |
|
recurrence |
180 |
|
polymerase chain reaction |
179 |
|
mortality |
178 |
|
reproducibility of results |
177 |
|
questionnaires |
174 |
|
disease progression |
173 |
|
dose-response relationship, drug |
173 |
|
cell proliferation |
171 |
|
signal transduction |
169 |
|
cross-sectional studies |
168 |
|
magnetic resonance imaging |
164 |
|
analysis of variance |
162 |
|
meta-analysis |
162 |
|
influenza |
159 |
|
sars-cov-2 |
156 |
|
predictive value of tests |
154 |
|
survival |
154 |
|
risk assessment |
153 |
|
phenotype |
152 |
|
rats, sprague-dawley |
150 |
|
transfection |
149 |
|
disease models, animal |
146 |
|
models, biological |
145 |
|
china - epidemiology |
143 |
|
dna methylation |
143 |
|
severity of illness index |
141 |
|
sex factors |
139 |
|
coronavirus |
138 |
|
rna, messenger - metabolism |
138 |
|
survival rate |
137 |
|
public health |
136 |
|
reference values |
136 |
|
breast cancer |
135 |
|
gene expression regulation, neoplastic |
134 |
|
mental health |
134 |
|
obesity |
134 |
|
cell differentiation |
132 |
|
diagnosis, differential |
131 |
|
infant, newborn |
130 |
|
survival analysis |
128 |
|
up-regulation |
128 |
|
diagnosis |
126 |
|
randomized controlled trial |
126 |
|
tomography, x-ray computed |
126 |
|
anxiety |
125 |
|
chemicals and cas registry numbers |
125 |
|
genetic predisposition to disease |
125 |
|
diabetes |
124 |
|
neoplasm staging |
124 |
|
asian continental ancestry group - genetics |
123 |
|
gene expression regulation |
122 |
|
dna primers |
121 |
|
tumor cells, cultured |
121 |
|
oxidative stress |
120 |
|
promoter regions, genetic |
120 |
|
surgery |
120 |
|
apoptosis - drug effects |
119 |
|
asia |
119 |
|
chronic disease |
119 |
|
enzyme-linked immunosorbent assay |
119 |
|
stroke |
119 |
|
algorithms |
118 |
|
chemotherapy |
118 |
|
hypertension |
115 |
|
logistic models |
115 |
|
treatment |
115 |
|
mice, inbred c57bl |
113 |
|
oncology |
113 |
|
polymorphism, genetic |
113 |
|
diabetes mellitus |
112 |
|
mice, inbred balb c |
112 |
|
acute disease |
111 |
|
disease outbreaks |
111 |
|
gene expression profiling |
111 |
|
statistics, nonparametric |
111 |
|
biomarker |
110 |
|
metastasis |
110 |
|
cell proliferation - drug effects |
109 |
|
colorectal cancer |
108 |
|
transcription, genetic |
108 |
|
body mass index |
107 |
|
flow cytometry |
107 |
|
infection |
107 |
|
cytokines |
106 |
|
down-regulation |
106 |
|
sequence analysis, dna |
106 |
|
animal experiment |
105 |
|
in situ hybridization |
105 |
|
phylogeny |
105 |
|
stress |
104 |
|
regression analysis |
103 |
|
alleles |
101 |
|
controlled study |
101 |
|
elderly |
101 |
|
multivariate analysis |
101 |
|
polymorphism, single nucleotide |
101 |
|
promoter regions, genetic - genetics |
101 |
|
biology |
100 |
|
combined modality therapy |
100 |
|
mutation - genetics |
100 |
|
cardiovascular disease |
99 |
|
chi-square distribution |
99 |
|
china - ethnology |
99 |
|
angiogenesis |
97 |
|
kinetics |
97 |
|
dna mutational analysis |
96 |
|
physical activity |
95 |
|
proteomics |
95 |
|
blood pressure |
94 |
|
phosphorylation |
94 |
|
radiotherapy |
94 |
|
smoking |
93 |
|
aging |
92 |
|
rna, messenger - genetics - metabolism |
92 |
|
biopsy |
90 |
|
animal model |
89 |
|
cloning, molecular |
89 |
|
longitudinal studies |
89 |
|
systematic review |
89 |
|
vaccination |
89 |
|
exercise |
88 |
|
fatal outcome |
88 |
|
mice, nude |
88 |
|
prevention |
88 |
|
screening |
88 |
|
age distribution |
87 |
|
enzyme inhibitors - pharmacology |
87 |
|
review |
87 |
|
adolescents |
86 |
|
cell cycle |
86 |
|
protein binding |
86 |
|
rna, messenger - analysis |
86 |
|
genetic variation |
85 |
|
biomarkers |
84 |
|
cluster analysis |
84 |
|
complications |
84 |
|
fibrosis |
83 |
|
sars |
83 |
|
cardiovascular diseases |
82 |
|
pilot projects |
82 |
|
schizophrenia |
82 |
|
temperature |
82 |
|
pandemic |
81 |
|
double-blind method |
80 |
|
immunotherapy |
80 |
|
outcome |
80 |
|
sequence homology, amino acid |
80 |
|
lung cancer |
79 |
|
neoplasm metastasis |
79 |
|
comorbidity |
78 |
|
gene deletion |
78 |
|
microrna |
78 |
|
microscopy, electron |
78 |
|
neoplasm invasiveness |
78 |
|
osteoporosis |
78 |
|
amino acid substitution |
77 |
|
drug therapy, combination |
77 |
|
liver cancer |
77 |
|
mouse |
77 |
|
autophagy |
76 |
|
gene frequency |
76 |
|
genetics |
76 |
|
health-related quality of life |
76 |
|
polymerase chain reaction - methods |
76 |
|
proliferation |
76 |
|
cell movement |
75 |
|
education |
75 |
|
liver transplantation |
75 |
|
risk factor |
75 |
|
safety |
75 |
|
swine |
75 |
|
type 2 diabetes |
75 |
|
binding sites |
74 |
|
cell division |
74 |
|
mitochondria |
74 |
|
nf-κb |
74 |
|
older adults |
74 |
|
rat |
74 |
|
cricetinae |
73 |
|
disease-free survival |
73 |
|
epstein-barr virus |
73 |
|
fluorescent antibody technique |
73 |
|
hcc |
73 |
|
hypoxia |
73 |
|
risk |
73 |
|
biological markers - blood |
72 |
|
depressive symptoms |
72 |
|
gene silencing |
72 |
|
hospitalization |
72 |
|
magnetic resonance imaging - methods |
72 |
|
hela cells |
71 |
|
nf-kappa b - metabolism |
71 |
|
pathogenesis |
71 |
|
adiponectin |
70 |
|
body weight |
70 |
|
genes, tumor suppressor |
70 |
|
mice, knockout |
70 |
|
viral load |
70 |
|
administration, oral |
69 |
|
atherosclerosis |
69 |
|
mice, transgenic |
69 |
|
oligonucleotide array sequence analysis |
69 |
|
p53 |
69 |
|
pain |
69 |
|
probability |
69 |
|
reliability |
69 |
|
sequence alignment |
69 |
|
socioeconomic factors |
69 |
|
antiviral agents - therapeutic use |
68 |
|
gastric cancer |
68 |
|
immunoenzyme techniques |
68 |
|
in situ hybridization, fluorescence |
68 |
|
nitric oxide |
68 |
|
transplantation |
68 |
|
validation |
68 |
|
age |
67 |
|
animal cell |
67 |
|
mri |
67 |
|
reactive oxygen species |
67 |
|
dementia |
66 |
|
gastroenterology |
66 |
|
influenza a virus |
66 |
|
intervention |
66 |
|
odds ratio |
66 |
|
rabbits |
66 |
|
severe acute respiratory syndrome |
66 |
|
signal transduction - drug effects |
66 |
|
tissue distribution |
66 |
|
type 2 diabetes mellitus |
66 |
|
validity |
66 |
|
bone marrow transplantation |
65 |
|
gene expression regulation - drug effects |
65 |
|
heterozygote |
65 |
|
methylation |
65 |
|
nursing |
65 |
|
polymorphism, single nucleotide - genetics |
65 |
|
alzheimer's disease |
64 |
|
influenza virus |
64 |
|
macrophages |
64 |
|
morbidity |
64 |
|
myocardial infarction |
64 |
|
nucleic acid hybridization |
64 |
|
sex distribution |
64 |
|
traditional chinese medicine |
64 |
|
differentiation |
63 |
|
liver |
63 |
|
postoperative complications |
63 |
|
health knowledge, attitudes, practice |
62 |
|
proportional hazards models |
62 |
|
rna interference |
62 |
|
rna, messenger - genetics |
62 |
|
antineoplastic agents - pharmacology |
61 |
|
chromosome aberrations |
61 |
|
cognition |
61 |
|
cytokine |
61 |
|
enzyme activation |
61 |
|
palliative care |
61 |
|
protein structure, tertiary |
61 |
|
vaccine |
61 |
|
animal tissue |
60 |
|
anti-bacterial agents - therapeutic use |
60 |
|
antiviral |
60 |
|
cell division - drug effects |
60 |
|
evolution, molecular |
60 |
|
heart failure |
60 |
|
hepatitis b virus |
60 |
|
pedigree |
60 |
|
pneumonia |
60 |
|
reverse transcriptase polymerase chain reaction - methods |
60 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
58 |
|
cervical cancer |
58 |
|
clinical trial |
58 |
|
drug resistance |
58 |
|
health status |
58 |
|
lymphatic metastasis |
58 |
|
point mutation |
58 |
|
signal transduction - physiology |
58 |
|
age of onset |
57 |
|
cell survival |
57 |
|
dna damage |
57 |
|
gene amplification |
57 |
|
health surveys |
57 |
|
hepatitis b |
57 |
|
homozygote |
57 |
|
patient satisfaction |
57 |
|
polymorphism, restriction fragment length |
57 |
|
psychometrics |
57 |
|
random allocation |
57 |
|
asian |
56 |
|
cattle |
56 |
|
coronary artery disease |
56 |
|
development |
56 |
|
helicobacter pylori |
56 |
|
models, molecular |
56 |
|
neuroprotection |
56 |
|
transcription factors - genetics |
56 |
|
wound healing |
56 |
|
antineoplastic agents - therapeutic use |
55 |
|
assessment |
55 |
|
asthma |
55 |
|
case report |
55 |
|
cisplatin |
55 |
|
dna-binding proteins - genetics |
55 |
|
dogs |
55 |
|
immunity |
55 |
|
population surveillance |
55 |
|
psychiatric status rating scales |
55 |
|
ultrasound |
55 |
|
virus replication |
55 |
|
biological markers |
54 |
|
cost-benefit analysis |
54 |
|
diet |
54 |
|
dna-binding proteins - genetics - metabolism |
54 |
|
family |
54 |
|
gene therapy |
54 |
|
ischemic stroke |
54 |
|
metabolic syndrome |
54 |
|
prediction |
54 |
|
telomerase |
54 |
|
transcription factors - genetics - metabolism |
54 |
|
acupuncture |
53 |
|
forecasting |
53 |
|
linear models |
53 |
|
metabolism |
53 |
|
syndrome |
53 |
|
transmission |
53 |
|
alanine transaminase - blood |
52 |
|
chromosome mapping |
52 |
|
chronic kidney disease |
52 |
|
coronavirus disease 2019 |
52 |
|
curriculum |
52 |
|
gender |
52 |
|
intracellular signaling peptides and proteins |
52 |
|
mass screening |
52 |
|
membrane proteins - genetics - metabolism |
52 |
|
psychosis |
52 |
|
seasons |
52 |
|
smoking cessation |
52 |
|
stem cells |
52 |
|
targeted therapy |
52 |
|
tuberculosis |
52 |
|
asia - epidemiology |
51 |
|
atrial fibrillation |
51 |
|
carcinoma |
51 |
|
cell survival - drug effects |
51 |
|
exons |
51 |
|
gestational age |
51 |
|
molecular epidemiology |
51 |
|
mutagenesis, site-directed |
51 |
|
parkinson's disease |
51 |
|
psychiatry and neurology |
51 |
|
serology |
51 |
|
animals, newborn |
50 |
|
carcinogenesis |
50 |
|
confidence intervals |
50 |
|
endocrinology |
50 |
|
image processing, computer-assisted |
50 |
|
karyotyping |
50 |
|
knowledge |
50 |
|
loss of heterozygosity |
50 |
|
microbial sensitivity tests |
50 |
|
polymorphism |
50 |
|
registries |
50 |
|
sars-cov |
50 |
|
sequence deletion |
50 |
|
systemic lupus erythematosus |
50 |
|
vitamin d |
50 |
|
brain |
49 |
|
calcium - metabolism |
49 |
|
chromosome deletion |
49 |
|
computer simulation |
49 |
|
data collection |
49 |
|
disease severity |
49 |
|
drug administration schedule |
49 |
|
family health |
49 |
|
genome, viral |
49 |
|
laparoscopy |
49 |
|
length of stay |
49 |
|
management |
49 |
|
migration |
49 |
|
priority journal |
49 |
|
rna, messenger - biosynthesis |
49 |
|
ultrasonography |
49 |
|
chinese medicine |
48 |
|
chromatography, high pressure liquid |
48 |
|
confirmatory factor analysis |
48 |
|
coronavirus infection |
48 |
|
culture |
48 |
|
dna, viral - analysis |
48 |
|
gene expression regulation, developmental |
48 |
|
genomics |
48 |
|
h5n1 |
48 |
|
hydrogen-ion concentration |
48 |
|
pediatrics |
48 |
|
species specificity |
48 |
|
transplantation, heterologous |
48 |
|
attitude |
47 |
|
blotting, northern |
47 |
|
cell movement - drug effects |
47 |
|
cirrhosis |
47 |
|
cost-effectiveness |
47 |
|
cytology and histology |
47 |
|
dna, viral - genetics |
47 |
|
electrophoresis, polyacrylamide gel |
47 |
|
genetic predisposition to disease - genetics |
47 |
|
genome |
47 |
|
genome-wide association study |
47 |
|
immune response |
47 |
|
mass screening - methods |
47 |
|
microarray |
47 |
|
molecular weight |
47 |
|
necrosis |
47 |
|
nuclear proteins - genetics - metabolism |
47 |
|
prognostic factors |
47 |
|
sleep |
47 |
|
social support |
47 |
|
cell nucleus - metabolism |
46 |
|
colon cancer |
46 |
|
dna - genetics |
46 |
|
drug synergism |
46 |
|
e-cadherin |
46 |
|
educational status |
46 |
|
esophageal cancer |
46 |
|
glycosylation |
46 |
|
hepatitis |
46 |
|
immunosuppressive agents - therapeutic use |
46 |
|
insulin resistance |
46 |
|
invasion |
46 |
|
microsatellite repeats |
46 |
|
outcomes |
46 |
|
rehabilitation |
46 |
|
rna, small interfering - genetics |
46 |
|
squamous cell carcinoma |
46 |
|
vegf |
46 |
|
antibodies, viral - blood |
45 |
|
chemoradiotherapy |
45 |
|
cytotoxicity |
45 |
|
dna primers - genetics |
45 |
|
ebv |
45 |
|
fatigue |
45 |
|
interferon |
45 |
|
interleukin-6 |
45 |
|
liver - metabolism |
45 |
|
peritoneal dialysis |
45 |
|
randomized controlled trials as topic |
45 |
|
statistics as topic |
45 |
|
transcription factors - metabolism |
45 |
|
alternative splicing |
44 |
|
attitude to health |
44 |
|
bioinformatics |
44 |
|
cause of death |
44 |
|
cell line, transformed |
44 |
|
cell migration |
44 |
|
dna |
44 |
|
dna, neoplasm - genetics |
44 |
|
early diagnosis |
44 |
|
endoscopy |
44 |
|
esophageal squamous cell carcinoma |
44 |
|
evolution |
44 |
|
immunoblotting |
44 |
|
neoplasm transplantation |
44 |
|
non-small cell lung cancer |
44 |
|
plasmids |
44 |
|
primary care |
44 |
|
transplantation, homologous |
44 |
|
tumor markers, biological - metabolism |
44 |
|
asian continental ancestry group - statistics & numerical data |
43 |
|
attitude of health personnel |
43 |
|
autoimmunity |
43 |
|
blotting, southern |
43 |
|
bronchiectasis |
43 |
|
community |
43 |
|
efficacy |
43 |
|
glaucoma |
43 |
|
head and neck cancer |
43 |
|
liver - pathology |
43 |
|
mesenchymal stem cells |
43 |
|
nomogram |
43 |
|
predictors |
43 |
|
reactive oxygen species - metabolism |
43 |
|
regeneration |
43 |
|
relapse |
43 |
|
rheumatoid arthritis |
43 |
|
sex characteristics |
43 |
|
tumor markers, biological - analysis |
43 |
|
akt |
42 |
|
antibody |
42 |
|
brain - pathology |
42 |
|
carrier proteins - genetics |
42 |
|
cell count |
42 |
|
cell death |
42 |
|
cholesterol |
42 |
|
complication |
42 |
|
computed tomography |
42 |
|
feasibility studies |
42 |
|
gene expression - drug effects |
42 |
|
genetic markers |
42 |
|
genetic vectors |
42 |
|
kidney |
42 |
|
machine learning |
42 |
|
mass spectrometry |
42 |
|
medical education |
42 |
|
models, animal |
42 |
|
neoplasm recurrence, local |
42 |
|
oncology medical sciences |
42 |
|
outcome assessment (health care) |
42 |
|
plasma |
42 |
|
rna, viral - genetics |
42 |
|
tumorigenesis |
42 |
|
body height |
41 |
|
cancer stem cells |
41 |
|
cell adhesion |
41 |
|
chinese women |
41 |
|
diffusion |
41 |
|
electrophoretic mobility shift assay |
41 |
|
escherichia coli |
41 |
|
h7n9 |
41 |
|
hippocampus |
41 |
|
immunocompromised host |
41 |
|
immunosuppression |
41 |
|
in situ nick-end labeling |
41 |
|
microscopy, electron, scanning |
41 |
|
mutations |
41 |
|
roc curve |
41 |
|
sorafenib |
41 |
|
suicide |
41 |
|
therapeutics |
41 |
|
animal |
40 |
|
apoptosis - physiology |
40 |
|
association |
40 |
|
caspases - metabolism |
40 |
|
cell transformation, neoplastic |
40 |
|
chemoresistance |
40 |
|
chemotherapy, adjuvant |
40 |
|
clinical competence |
40 |
|
clinical trials |
40 |
|
cognitive impairment |
40 |
|
decision making |
40 |
|
drug resistance, neoplasm |
40 |
|
electrophysiology |
40 |
|
environment |
40 |
|
epigenetics |
40 |
|
haplotypes |
40 |
|
herbal medicine |
40 |
|
infection control |
40 |
|
macrophage |
40 |
|
menopause |
40 |
|
molecular sequence numbers |
40 |
|
mutation, missense |
40 |
|
organ size |
40 |
|
organ specificity |
40 |
|
ovarian cancer |
40 |
|
prostate cancer |
40 |
|
proteins - genetics |
40 |
|
proteins - metabolism |
40 |
|
recombination, genetic |
40 |
|
referral and consultation |
40 |
|
reoperation |
40 |
|
stem cell |
40 |
|
susceptibility |
40 |
|
tumor microenvironment |
40 |
|
vascular endothelial growth factor |
40 |
|
β-catenin |
40 |
|
antibodies |
39 |
|
attitudes |
39 |
|
calcium |
39 |
|
coculture techniques |
39 |
|
dna-binding proteins - metabolism |
39 |
|
epigenesis, genetic |
39 |
|
equipment design |
39 |
|
evaluation |
39 |
|
graft survival |
39 |
|
hong kong chinese |
39 |
|
immunization |
39 |
|
kidney transplantation |
39 |
|
metabolomics |
39 |
|
pharmacokinetics |
39 |
|
problem-based learning |
39 |
|
radioimmunoassay |
39 |
|
sequence homology, nucleic acid |
39 |
|
seroepidemiologic studies |
39 |
|
single nucleotide polymorphism |
39 |
|
surveillance |
39 |
|
avian influenza |
38 |
|
blood glucose - metabolism |
38 |
|
cadherins - metabolism |
38 |
|
cell differentiation - physiology |
38 |
|
classification |
38 |
|
clinical trials as topic |
38 |
|
communication |
38 |
|
diffusion tensor imaging |
38 |
|
dna, complementary - genetics |
38 |
|
dna, viral - blood |
38 |
|
drug interactions |
38 |
|
effectiveness |
38 |
|
health |
38 |
|
hiv |
38 |
|
immunoglobulin g - blood |
38 |
|
induced pluripotent stem cells |
38 |
|
intraocular pressure |
38 |
|
linkage disequilibrium |
38 |
|
lung |
38 |
|
models, genetic |
38 |
|
neoplasm proteins - metabolism |
38 |
|
practice guidelines as topic |
38 |
|
primary health care |
38 |
|
psychotic disorders |
38 |
|
resistance |
38 |
|
retina |
38 |
|
structure-activity relationship |
38 |
|
testosterone |
38 |
|
aging - physiology |
37 |
|
blood transfusion |
37 |
|
chronic hepatitis b |
37 |
|
collagen |
37 |
|
disease outbreaks - statistics & numerical data |
37 |
|
epidermal growth factor receptor |
37 |
|
gene expression regulation, neoplastic - genetics |
37 |
|
gene mutation |
37 |
|
glycoproteins - metabolism |
37 |
|
homeodomain proteins - genetics - metabolism |
37 |
|
insomnia |
37 |
|
lipids |
37 |
|
liver neoplasms - metabolism - pathology |
37 |
|
lymphocyte activation |
37 |
|
medicine & public health |
37 |
|
micrornas - genetics - metabolism |
37 |
|
mtor |
37 |
|
neoplasm proteins - genetics - metabolism |
37 |
|
patient selection |
37 |
|
pediatric |
37 |
|
prenatal diagnosis |
37 |
|
smoking - adverse effects |
37 |
|
transcription factors |
37 |
|
tumor suppressor protein p53 - metabolism |
37 |
|
carrier proteins - metabolism |
36 |
|
cell cycle - drug effects |
36 |
|
cercopithecus aethiops |
36 |
|
cross-cultural comparison |
36 |
|
dopamine |
36 |
|
early intervention |
36 |
|
evaluation studies as topic |
36 |
|
genes |
36 |
|
hemagglutinin |
36 |
|
hepatectomy |
36 |
|
human papillomavirus |
36 |
|
influenza a virus, h1n1 subtype - immunology |
36 |
|
membrane proteins - genetics |
36 |
|
models, statistical |
36 |
|
motivation |
36 |
|
outbreak |
36 |
|
pandemics |
36 |
|
polymorphism, genetic - genetics |
36 |
|
rna, viral - analysis |
36 |
|
spinal cord |
36 |
|
stents |
36 |
|
t-lymphocytes - immunology |
36 |
|
t-lymphocytes, cytotoxic - immunology |
36 |
|
tumor suppressor gene |
36 |
|
activities of daily living |
35 |
|
analgesia |
35 |
|
anti-bacterial agents - pharmacology |
35 |
|
antibiotics |
35 |
|
betacoronavirus |
35 |
|
biomechanics |
35 |
|
cadaver |
35 |
|
caspase |
35 |
|
data interpretation, statistical |
35 |
|
dendritic cells |
35 |
|
epidemiologic methods |
35 |
|
fluorescent antibody technique, indirect |
35 |
|
genetic susceptibility |
35 |
|
imaging |
35 |
|
immunoprecipitation |
35 |
|
internet |
35 |
|
interviews as topic |
35 |
|
ischemia |
35 |
|
language |
35 |
|
letter |
35 |
|
living donors |
35 |
|
mers-cov |
35 |
|
npc |
35 |
|
osteogenesis |
35 |
|
patient compliance |
35 |
|
recovery of function |
35 |
|
remission induction |
35 |
|
repressor proteins |
35 |
|
survey |
35 |
|
tobacco |
35 |
|
transcriptional activation |
35 |
|
tumor suppressor |
35 |
|
whole-exome sequencing |
35 |
|
antiviral therapy |
34 |
|
apoptosis - drug effects - physiology |
34 |
|
asian continental ancestry group - ethnology |
34 |
|
biochemistry |
34 |
|
biopsy, needle |
34 |
|
bone marrow |
34 |
|
bone marrow transplantation - adverse effects |
34 |
|
clinical article |
34 |
|
cohort |
34 |
|
cohort study |
34 |
|
demography |
34 |
|
diabetic retinopathy |
34 |
|
diffusion magnetic resonance imaging |
34 |
|
epidemic |
34 |
|
european continental ancestry group |
34 |
|
first-episode psychosis |
34 |
|
gene knockdown techniques |
34 |
|
genes, viral |
34 |
|
genetic testing |
34 |
|
intimate partner violence |
34 |
|
intracellular signaling peptides and proteins - genetics - metabolism |
34 |
|
lymph nodes - pathology |
34 |
|
models, theoretical |
34 |
|
neurogenesis |
34 |
|
neutralization tests |
34 |
|
oxidative stress - drug effects |
34 |
|
phosphorylation - drug effects |
34 |
|
rats, inbred strains |
34 |
|
sensitivity |
34 |
|
signaling |
34 |
|
adolescent idiopathic scoliosis |
33 |
|
antibodies, monoclonal - immunology |
33 |
|
antioxidants |
33 |
|
article |
33 |
|
biological markers - analysis |
33 |
|
caspase 3 |
33 |
|
cholesterol - blood |
33 |
|
cpg islands |
33 |
|
cytokines - biosynthesis |
33 |
|
cytokines - metabolism |
33 |
|
dna - metabolism |
33 |
|
dna-binding proteins |
33 |
|
embryonic stem cells |
33 |
|
endothelial cells |
33 |
|
enterovirus |
33 |
|
epithelial cells |
33 |
|
extracellular matrix |
33 |
|
gene expression regulation, neoplastic - drug effects |
33 |
|
guinea pigs |
33 |
|
health promotion |
33 |
|
heart |
33 |
|
herpesvirus 4, human - isolation & purification |
33 |
|
homeostasis |
33 |
|
hospitalization - statistics & numerical data |
33 |
|
ligands |
33 |
|
liver fibrosis |
33 |
|
liver function tests |
33 |
|
medicine, chinese traditional |
33 |
|
molecular biology |
33 |
|
molecular structure |
33 |
|
neoplasms |
33 |
|
nurses |
33 |
|
perception |
33 |
|
proto-oncogene proteins c-akt - metabolism |
33 |
|
pten |
33 |
|
questionnaire |
33 |
|
sars coronavirus |
33 |
|
sars virus - immunology |
33 |
|
signal transduction - genetics |
33 |
|
t cells |
33 |
|
two-hybrid system techniques |
33 |
|
world health organization |
33 |
|
adaptor proteins, signal transducing - genetics - metabolism |
32 |
|
adenovirus |
32 |
|
behavior |
32 |
|
binding, competitive |
32 |
|
blood pressure - drug effects |
32 |
|
cancer staging |
32 |
|
carcinoma, hepatocellular - metabolism - pathology |
32 |
|
cell membrane - metabolism |
32 |
|
circadian rhythm |
32 |
|
clone cells |
32 |
|
cognitive function |
32 |
|
coronary heart disease |
32 |
|
cross-over studies |
32 |
|
dna - analysis |
32 |
|
genes, reporter |
32 |
|
genome, human |
32 |
|
h1n1 |
32 |
|
immunology |
32 |
|
influenza a virus, h1n1 subtype - physiology |
32 |
|
influenza, human - epidemiology - virology |
32 |
|
insulin |
32 |
|
intracellular signaling peptides and proteins - genetics |
32 |
|
membrane glycoproteins - metabolism |
32 |
|
next-generation sequencing |
32 |
|
patient acceptance of health care |
32 |
|
pcr |
32 |
|
plant extracts - pharmacology |
32 |
|
proteomics - methods |
32 |
|
questionnaires - standards |
32 |
|
recombinant proteins - metabolism |
32 |
|
serotyping |
32 |
|
up-regulation - drug effects |
32 |
|
virulence |
32 |
|
women |
32 |
|
actins - metabolism |
31 |
|
adaptor proteins, signal transducing |
31 |
|
adenocarcinoma |
31 |
|
adolescence |
31 |
|
aneuploidy |
31 |
|
anisotropy |
31 |
|
blood pressure - physiology |
31 |
|
brain mapping |
31 |
|
carcinoma, squamous cell - genetics |
31 |
|
cell differentiation - drug effects |
31 |
|
child development |
31 |
|
drug combinations |
31 |
|
extracellular vesicles |
31 |
|
family characteristics |
31 |
|
gene expression regulation - physiology |
31 |
|
health status indicators |
31 |
|
herpesvirus 4, human - genetics |
31 |
|
hypermethylation |
31 |
|
influenza, human - virology |
31 |
|
learning |
31 |
|
life style |
31 |
|
lymphoma |
31 |
|
microsatellite repeats - genetics |
31 |
|
neoplasm proteins - genetics |
31 |
|
nuclear proteins |
31 |
|
promoter hypermethylation |
31 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
31 |
|
receptors, cell surface - metabolism |
31 |
|
resilience |
31 |
|
saliva |
31 |
|
spermatogenesis |
31 |
|
staging |
31 |
|
trauma |
31 |
|
world health |
31 |
|
25-hydroxyvitamin d |
30 |
|
amino acid motifs |
30 |
|
angiography |
30 |
|
asymptomatic |
30 |
|
autoantibodies - blood |
30 |
|
azacitidine - analogs & derivatives - pharmacology |
30 |
|
breastfeeding |
30 |
|
c-reactive protein |
30 |
|
cardiomyocytes |
30 |
|
cell transformation, neoplastic - genetics |
30 |
|
coronavirus disease |
30 |
|
covid‐19 |
30 |
|
drugs, chinese herbal - pharmacology |
30 |
|
electric stimulation |
30 |
|
electromyography |
30 |
|
electrophoresis, gel, two-dimensional |
30 |
|
estrogen |
30 |
|
extracellular signal-regulated map kinases - metabolism |
30 |
|
functioning |
30 |
|
gastroenterology medical sciences |
30 |
|
genetic association |
30 |
|
health policy |
30 |
|
hematopoietic stem cell transplantation |
30 |
|
hepatitis c virus |
30 |
|
infusions, intravenous |
30 |
|
injections, intravenous |
30 |
|
long-term outcome |
30 |
|
major clinical study |
30 |
|
mendelian randomization |
30 |
|
nasopharyngeal cancer |
30 |
|
neuroblastoma |
30 |
|
nuclear proteins - genetics |
30 |
|
organ culture techniques |
30 |
|
paediatrics |
30 |
|
postoperative period |
30 |
|
prediction model |
30 |
|
protein conformation |
30 |
|
research design |
30 |
|
respiratory diseases |
30 |
|
rna, messenger - biosynthesis - genetics |
30 |
|
rna, small interfering |
30 |
|
tissue engineering |
30 |
|
treatment failure |
30 |
|
united states |
30 |
|
violence |
30 |
|
adaptation, psychological |
29 |
|
adverse events |
29 |
|
bacteria |
29 |
|
biological transport |
29 |
|
birds - virology |
29 |
|
blood glucose - analysis |
29 |
|
bone density |
29 |
|
cancer chemotherapy |
29 |
|
cell cycle - physiology |
29 |
|
colonoscopy |
29 |
|
death |
29 |
|
enzyme activation - drug effects |
29 |
|
epithelial cells - pathology |
29 |
|
evidence-based medicine |
29 |
|
fibroblasts |
29 |
|
fracture |
29 |
|
functional outcome |
29 |
|
gene expression profiling - methods |
29 |
|
gene transfer techniques |
29 |
|
genes, p53 |
29 |
|
homeodomain proteins - genetics |
29 |
|
hong kong - ethnology |
29 |
|
immunity, innate |
29 |
|
immunomodulation |
29 |
|
immunophenotyping |
29 |
|
influenza a virus, h5n1 subtype |
29 |
|
kaplan-meier estimate |
29 |
|
magnetic resonance spectroscopy |
29 |
|
malignancy |
29 |
|
mapk |
29 |
|
metformin |
29 |
|
mice, scid |
29 |
|
microscopy, fluorescence |
29 |
|
mild cognitive impairment |
29 |
|
multigene family |
29 |
|
myocardium - metabolism |
29 |
|
negative symptoms |
29 |
|
neurodegeneration |
29 |
|
neurons - metabolism |
29 |
|
nuclear proteins - metabolism |
29 |
|
osmolar concentration |
29 |
|
osteoarthritis |
29 |
|
oxidation-reduction |
29 |
|
point mutation - genetics |
29 |
|
pregnancy outcome |
29 |
|
prognostic marker |
29 |
|
qualitative research |
29 |
|
secondary prevention |
29 |
|
species index: animalia |
29 |
|
testis |
29 |
|
toxicity |
29 |
|
transcription |
29 |
|
tumor suppressor proteins - genetics - metabolism |
29 |
|
vascular endothelial growth factor a - metabolism |
29 |
|
virus replication - drug effects |
29 |
|
xenograft model antitumor assays |
29 |
|
ageing |
28 |
|
allergy |
28 |
|
ampk |
28 |
|
antibody specificity |
28 |
|
beta catenin |
28 |
|
birds |
28 |
|
bone mineral density |
28 |
|
cancer stem cell |
28 |
|
capecitabine |
28 |
